127 related articles for article (PubMed ID: 16929616)
1. Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month.
Louis E; Jorissen P; Bastens B; D'Haens G; Schoofs N; Burette A; Christiaens P; Tack J;
Acta Gastroenterol Belg; 2006; 69(2):203-8. PubMed ID: 16929616
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
Dent J; Vakil N; Jones R; Bytzer P; Schöning U; Halling K; Junghard O; Lind T
Gut; 2010 Jun; 59(6):714-21. PubMed ID: 20551454
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of esomeprazole and fundoplication on airway responsiveness in patients with gastro-oesophageal reflux disease.
Kiljander T; Rantanen T; Kellokumpu I; Kööbi T; Lammi L; Nieminen M; Poussa T; Ranta A; Saarelainen S; Salminen P
Clin Respir J; 2013 Jul; 7(3):281-7. PubMed ID: 23006321
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor.
Jones R; Patrikios T
Int J Clin Pract; 2008 Dec; 62(12):1844-50. PubMed ID: 19166433
[TBL] [Abstract][Full Text] [Related]
5. The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
Thomson AB
Clin Drug Investig; 2007; 27(10):663-72. PubMed ID: 17803341
[TBL] [Abstract][Full Text] [Related]
6. Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.
Ekesbo R; Sjöstedt S; Sörngård H
Clin Drug Investig; 2011; 31(3):181-9. PubMed ID: 21288053
[TBL] [Abstract][Full Text] [Related]
7. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
Talley NJ; Venables TL; Green JR; Armstrong D; O'Kane KP; Giaffer M; Bardhan KD; Carlsson RG; Chen S; Hasselgren GS
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):857-63. PubMed ID: 12172406
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Wahlqvist P; Junghard O; Higgins A; Green J
Pharmacoeconomics; 2002; 20(4):267-77. PubMed ID: 11950383
[TBL] [Abstract][Full Text] [Related]
11. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
[TBL] [Abstract][Full Text] [Related]
12. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
[TBL] [Abstract][Full Text] [Related]
13. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Johnsson F; Hatlebakk JG; Klintenberg AC; Román J; Toth E; Stubberöd A; Falk A; Edin R
Scand J Gastroenterol; 2003 Apr; 38(4):354-9. PubMed ID: 12739706
[TBL] [Abstract][Full Text] [Related]
14. [Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study].
Beglinger C; Thalmann C; Szucs T; Michetti P
Praxis (Bern 1994); 2006 Mar; 95(13):483-7. PubMed ID: 16602668
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
17. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
Hoogendoorn RJ; Groeneveld L; Kwee JA
Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
[TBL] [Abstract][Full Text] [Related]
18. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
[TBL] [Abstract][Full Text] [Related]
19. The impact of intensifying acid suppression on sleep disturbance related to gastro-oesophageal reflux disease in primary care.
Moayyedi P; Hunt R; Armstrong D; Lei Y; Bukoski M; White R
Aliment Pharmacol Ther; 2013 Apr; 37(7):730-7. PubMed ID: 23432146
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
Monés J
Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
